AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01899729
Drug: IMO-8400 Regimen 4
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMO-8400 0.6 mg/kg q wk x 12 wk by subcutaneous injection
Trial: NCT03642873
Drug: Humibid®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humibid® 1200 mg (single extended release) tablet
Trial: NCT03642873
Drug: Humibid® and Hydrocodone Bitartrate tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humibid® 1200 mg (single extended release) tablet and Hydrocodone bitartrate (3.33 mg q4h X 3)
Trial: NCT02234843
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMWH (low molecular weight heparin) or fondaparinux or vitamin K antagonist (VKA) therapy.~dose : as per standard of care
Trial: NCT04227470
Drug: HBM9161 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection; Weekly administered for a period of 4 weeks. All subjects are treated with the testing drug, add on intravenous methylprednisolone (ivMP) with gradually reduce the dose then to oral prednisone. After the administration of the testing drug, if the subject's symptoms get worsen, a rescue therapy need to be adopted as based on Investigator's judgement, the testing drug injection should be discontinued.
Trial: NCT00841841
Drug: dipyrone and acetaminophen
RxNorm normalized name: acetaminophen / dipyrone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients were randomly assigned to 2 groups of 15 patients, according to the drug prescribed as postoperative medication: Group I: dipyrone 500 mg every 6 hours (4 males, 11 females, mean age = 25.2 years) and Group II: paracetamol 750 mg every 6 hours (3 males, 12 females, mean age = 26.8 years)
Trial: NCT01643499
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01643499
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04533061
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: influenza vaccine 0.5 ml intramuscularly each season~2004-2005 season contains: A/New Caledonia/20/99 (H1N1)-like, A/Fujian/411/2002 (H3N2-like), and B/Shanghai/361/2002-like antigens~2005-2006 season contains: A/New Caledonia/20/99 (H1N1)-like, A/California/7/2004 (H3N2), and B/Shanghai/361/2002-like antigens
Trial: NCT02959229
Drug: Placebo (for Lactoferrin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo in form of distilled water
Trial: NCT00909961
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02652585
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule filled with micro crystalline cellulose, manufactured to mimic naltrexone capsule
Trial: NCT03593642
Drug: Continuous infusion of ropivacain in ESP catheter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of ropivacaine in ESP catheter to provide regional analgesia after surgery
Trial: NCT03593642
Drug: Continuous infusion of Iso Saline in ESP catheter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of Iso Saline in ESP catheter to be the control group
Trial: NCT05055752
Drug: Pharmaceutical-lipid aspirin (PL-ASA)
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive the first drug, followed by a 7-day washout period, then receive the second drug.
Trial: NCT01078779
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules, 2 capsules daily for 7 days then 2 capsules weekly for a total treatment duration of 12 weeks
Trial: NCT02182479
Drug: Berodual® via Respimat®, high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02182479
Drug: Berodual® via Respimat®, low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02182479
Drug: Berodual® via MDI, high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02182479
Drug: Placebo Respimat®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02182479
Drug: Placebo MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04255979
Drug: HY209
RxNorm normalized name: Hydrocodone
DrugBank: Hydrocodone (DB00956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 Subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.
Trial: NCT01158885
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate to be given intrathecally (IT) to all acute lymphoblastic leukemia (ALL) patients on day 1 at the dose defined by age below:~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age
Trial: NCT04127669
Drug: OSU 6162
RxNorm normalized name: Osurnia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The active ingredient of OSU6162 is the S-enantiomer with the chemical name (S)-3-\[3-(methylsulfonyl)phenyl\]-1-propylpiperidine hydrochloride. The substance is a white powder with a melting point of 177-182°C. Solubility in water is \> 2000 mg/ml. Current laboratory code used is OSU6162-HCl. In trial protocol, OSU6162-HCl is shortened to OSU6162.
Trial: NCT04127669
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circular coated tablet (with identical appearance to active treatment tablets 15 mg).
Trial: NCT03750968
Drug: Carotenoid Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Softgel active ingredients: Lutein 10 mg and Zeaxanthin 2 mg in safflower oil
Trial: NCT01350999
Drug: Eicosapentaenoic acid-ethyl (EPA)
RxNorm normalized name: Eicosapentaenoic acid ethyl ester
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: EPA-E capsules
Trial: NCT00879021
Drug: matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg by mouth ,twice a day for 49 weeks
Trial: NCT00070694
Drug: MDL100.907
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03859869
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered orally as capsules with a meal or snack
Trial: NCT02220660
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02778659
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.
Trial: NCT04325685
Drug: Bacteriophage
RxNorm normalized name: bacteriophages
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oropharyngeal decontamination with bacteriophage will be performing three time a day every 8 hours during mechanical ventilation
Trial: NCT01571570
Drug: TMC435 150 mg capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose of 150 mg TMC435 150 mg capsule
Trial: NCT01571570
Drug: TMC435 150 mg oral suspension (20 mg/mL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose of 150 mg TMC435 oral suspension
Trial: NCT01571570
Drug: TMC435 150 mg oral solution (10 mg/mL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose of 150 mg TMC435 oral solution
Trial: NCT01571570
Drug: TMC435 150 mg capsule concept K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose of 150 mg TMC435 capsule concept K
Trial: NCT01571570
Drug: TMC435 150 mg capsule concept L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose of 150 mg TMC435 capsule concept L
Trial: NCT03582722
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be instructed to take one placebo capsule to match 60mg of orlistat with each meal containing fat, up to three capsules daily, for six months.
Trial: NCT01678794
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated
Trial: NCT02772601
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03647423
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capsules
Trial: NCT01733420
Drug: Biodentine pulpotomy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01733420
Drug: Tempophore pulpotomy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00179621
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, matching to active study drug arms
Trial: NCT00291616
Drug: Thymosin alpha1 & Pegylated Interferon-alpha2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated interferon 180 microgram s.c. injection weekly Thymosin 1.6 mg s.c. injection twice per week
Trial: NCT04029649
Drug: Beta-1,3/1,6-D-Glucan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-1,3/1,6-D-Glucan capsule three times daily for 90 days
Trial: NCT01395797
Drug: PIO
RxNorm normalized name: PIO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0, 15, and 45 mg per day.
Trial: NCT01395797
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01997333
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02237417
Drug: Standard of Care Oral antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 15 to 20 subjects with schizophrenia will receive SOC oral antipsychotic medications (e.g., aripiprazole (Abilify®), risperidone (Risperdal®), lurasidone HCI (Latuda®), quetiapine fumarate (Seroquel®), olanzapine (Zyprexa®), and ziprasidone HCI(Geodon®)) or once monthly aripiprazole (Abilify®), PO daily, in accordance with their respective product labeling.
Trial: NCT01500590
Drug: Renin-angiotensin system blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ramipril 2.5mg to 10mg once daily if patient experience cough, we will use irbesartan 150 mg to 300mg once daily
Trial: NCT01500590
Drug: non-renin angiotensin system blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amlodipine 2.5 to 10 mg once daily nifedipine retard 20mg to 40mg twice daily indapamide 2.5mg once daily metoprolol 25mg to 100mg daily methyldopa 125 mg to 500mg twice daily
Trial: NCT01908426
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00805350
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of Eplivanserin one tablet once a day
Trial: NCT01095185
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg for 15 days, then 40 mg until the end of the study.
Trial: NCT01095185
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin placebo
Trial: NCT03721068
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/m\^2 IV dose on days 1-2 for lymphodepletion prior to cell infusion
Trial: NCT03947827
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to receive either Minocycline or placebo added to standard oral antidepressants.
Trial: NCT01647789
Drug: CFG920
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00379535
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: per os
Trial: NCT00242268
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00575185
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets orally twice daily for 21 days.
Trial: NCT02172430
Drug: Tersigan®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 puffs of oxitropium three times daily via MDI
Trial: NCT00001483
Drug: buproprion (Wellbutrin)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03056209
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration, placebo
Trial: NCT01110889
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005984
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenously over 2 hours on day 1 and on days -7 and -6
Trial: NCT00414635
Drug: Intermitent Dosing
RxNorm normalized name: CATH,INTERMIT,14FR MENTOR #3814
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent dosing treatment is the maintenance of the 5/2 schedule, where the regimen, 300 mg tenofovir td, 600 mg efavirenz, 200 mg emtricitabine is dosed for 5 consecutive days - typically Monday through Friday - followed by two days off of medication, 300 mg tenofovir td, 600 mg efavirenz, 200 mg emtricitabine. .
Trial: NCT02421172
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00991861
Drug: LAS41007 o.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, topical application
Trial: NCT00991861
Drug: LAS41007 b.i.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily, topical application
Trial: NCT00991861
Drug: LAS106521
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily, topical application
Trial: NCT04301375
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant endocrine therapy will be administered as per local practice and according to recognized clinical practice guidelines
Trial: NCT02053597
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will receive four cycles of doxorubicin (A) (50 mg/m2)
Trial: NCT01841281
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients.
Trial: NCT04527887
Drug: Dextenza (IDI) (Sustained Release Dexamethasone), (0.4 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracanalicular dexamethasone insert contains 0.4 mg dexamethasone and is designed to provide a sustained and tapered release of therapeutic levels of dexamethasone to the ocular surface for up to 30 days for the reduction of postsurgical inflammation and pain associated with ocular surgery.
Trial: NCT00966836
Drug: Prophylaxis with valganciclovir plus mycophenolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 3 months of oral valganciclovir with mycophenolate and standard cyclosporine and prednisone for maintenance immunosuppression
Trial: NCT00966836
Drug: Pre-emptive mycophenolate
RxNorm normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be monitored for CMV infection and receive valganciclovir only for positive PCR or antigenemia. Mycophenolate plus standard cyclosporine and prednisone will be used for maintenance immunosuppression
Trial: NCT03177902
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newly diagnosed breast cancer patients undergoing at least four cycles of chemotherapy.
Trial: NCT00431990
Drug: depsipeptide
RxNorm normalized name: palmitoyl dipeptide-7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1. Dose escalation, IV, Weeklyx3 in a 4week cycle. Cohort 2A. 12mg/m2, IV, Weeklyx3 in a 4week cycle. Cohort 2B. 12mg/m2, IV, Weeklyx2 in a 3week cycle.
Trial: NCT04219254
Drug: BI1206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI-1206 administrated either IV or SC every third week. Pembrolizumab 200mg administered IV every third week as a fixed dose will be used in Phase 1 and IIa.~The mTPI2 Design will be used for both the IV and SC cohorts. ivRP2D and scRP2D to be used in Phase
Trial: NCT01275352
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eplerenone 50 mg/day
Trial: NCT00724334
Drug: SAR302503 (TG101348)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally administered, once a day
Trial: NCT01275352
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03059940
Drug: Anti-Smoking Drug
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline or Buproprion prescribed by study doctor with directions of when and how much of anti-smoking drug that should be taken each time.
Trial: NCT00783523
Drug: Doxycycline or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized to Doxycycline 100mg 2x/day or Placebo 2x/day for 1 or2-weeks pre-operatively.
Trial: NCT04184466
Drug: NovoRapid® Penfill®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: insulin aspart in doses 0.3 IU/kg
Trial: NCT01277666
Drug: GSK1605786A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg twice daily, administered orally for 12 weeks
Trial: NCT01277666
Drug: GSK1605786A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg once daily, administered orally for 12 weeks
Trial: NCT01277666
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules, administered orally for 12 weeks
Trial: NCT04226365
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg capsule Thick-It filler
Trial: NCT04164199
Drug: BAT1706
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously.
Trial: NCT04164199
Drug: LBL-007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously.
Trial: NCT02647281
Drug: GSK3389404
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3389404 is supplied as solution for injection vial. Each vial contains 100 mg/mL of GSK3389404. It's physical appearance is clear colourless to slightly yellow solution.
Trial: NCT02647281
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is supplied as solution for injection vial. It's physical appearance is clear colourless solution.
Trial: NCT03291067
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo QD, oral, 12 weeks
Trial: NCT04151758
Drug: Docosahexaenoic Acid Supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docosahexaenoic Acid (DHA) will be given at the dose of 500 mg/day (2 ml per day DHA RICH OIL 25% aroma mandorla FoodAR Limbiate, Italy;50% DHA oil obtained from Schyzochitrium sp ; Martek Biosciences Corporation, Columbia, Maryland, USA) to all participants of the study. DHA 2 ml will provide about 16 kcal of energy.
Trial: NCT01838694
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04235140
Drug: LUM/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LUM/IVA granules for oral administration
Trial: NCT03246971
Drug: Wafermine™ 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as needed for 12 hours
Trial: NCT03246971
Drug: Wafermine™ 75 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as needed for 12 hours
Trial: NCT03246971
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as needed for 12 hours
Trial: NCT03246971
Drug: Wafermine™ 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as needed for 12 hours
Trial: NCT00315926
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin 50 mg during surgery and 10 mg every night for 3 nights
Trial: NCT00315926
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a mixture of ethanol and physiological saline
Trial: NCT02446977
Drug: Vitamin B2 Streuli®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4ml IV
Trial: NCT01176201
Drug: SLV337 suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg experimental
Trial: NCT01176201
Drug: SLV337 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 x 200 mg immediate release capsule
Trial: NCT01194830
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 Tablet PO QD
Trial: NCT00148278
Drug: norepinephrine and dobutamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuous infusion of norepinephrine titrated to maintain a mean arterial pressure at 70mmHg or more and dobutamine could be added as a continuous infusion when cardiac index was of less than 2.5 liters per squared meter of body surface
Trial: NCT00148278
Drug: epinephrine plus placebo of dobutamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epinephrine was titrated to maintain a mean arterial pressure at 70mmHg or more and placebo of dobutamine was titrated in case of a cardiac index lower than 2.5 liters per squared meters of body surface
Trial: NCT03562195
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given as 0.9 percent sodium chloride solution.
Trial: NCT01854918
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
Trial: NCT03590613
Drug: GSK2982772
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route